Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation

The low-density lipoprotein-cholesterol (LDL-C) level of a 38-year-old man diagnosed with acute coronary syndrome was 257 mg/dL. The administration of a proprotein convertase subtilisin-kexin type 9 (PCSK9) antibody in addition to rosuvastatin plus ezetimibe was initiated, reducing his LDL-C level t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirahama, Ryo, Ono, Takamichi, Nagamatsu, Suguru, Sueta, Daisuke, Takashio, Seiji, Chitose, Tadasuke, Fujisue, Koichiro, Sakamoto, Kenji, Yamamoto, Eiichiro, Izumiya, Yasuhiro, Kaikita, Koichi, Hokimoto, Seiji, Hori, Mika, Harada-Shiba, Mariko, Kajiwara, Ichiro, Ogawa, Hisao, Tsujita, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355420/
https://www.ncbi.nlm.nih.gov/pubmed/30555118
http://dx.doi.org/10.2169/internalmedicine.1060-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355420/
https://www.ncbi.nlm.nih.gov/pubmed/30555118
http://dx.doi.org/10.2169/internalmedicine.1060-18

Ejemplares similares